[Skip to content]

Cancer Advice - from leading UK Cancer Specialists
Find information
In this section...
On this site...

Oral Ibandronate reduces the development of new bone metastases in breast cancer

A recently reported study from Texas demonstrated that oral administration of ibandronate (a very potent third generation bisphosphonate) significantly reduced the incidence of new skeletal/bone metastases in breast cancer patients with metastatic bone disease. The mean number of new events per patient was 1.36 for patients taking ibandronate and 2.23 for patients on placebo. A dose of 50mg per day seemed optimal. This study is another one suggesting that bisphonate administration makes it more difficult for cancer to get a "toehold" and progress in bone.